TWI858393B - 介白素２突變體以及其融合蛋白 - Google Patents

介白素２突變體以及其融合蛋白 Download PDF

Info

Publication number
TWI858393B
TWI858393B TW111135759A TW111135759A TWI858393B TW I858393 B TWI858393 B TW I858393B TW 111135759 A TW111135759 A TW 111135759A TW 111135759 A TW111135759 A TW 111135759A TW I858393 B TWI858393 B TW I858393B
Authority
TW
Taiwan
Prior art keywords
amino acid
antibody
seq
acid sequence
cells
Prior art date
Application number
TW111135759A
Other languages
English (en)
Chinese (zh)
Other versions
TW202320862A (zh
Inventor
何開杰
付鳳根
伍偉偉
周帥祥
關劍
Original Assignee
新加坡商信達生物製藥（新加坡）有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 新加坡商信達生物製藥（新加坡）有限公司 filed Critical 新加坡商信達生物製藥（新加坡）有限公司
Publication of TW202320862A publication Critical patent/TW202320862A/zh
Application granted granted Critical
Publication of TWI858393B publication Critical patent/TWI858393B/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
TW111135759A 2021-09-22 2022-09-21 介白素２突變體以及其融合蛋白 TWI858393B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202111110032 2021-09-22
CN202111110032.3 2021-09-22

Publications (2)

Publication Number Publication Date
TW202320862A TW202320862A (zh) 2023-06-01
TWI858393B true TWI858393B (zh) 2024-10-11

Family

ID=85720093

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111135759A TWI858393B (zh) 2021-09-22 2022-09-21 介白素２突變體以及其融合蛋白

Country Status (14)

Country Link
US (2) US20240391973A1 (https=)
EP (1) EP4406965A4 (https=)
JP (1) JP2024534545A (https=)
KR (1) KR20240082364A (https=)
CN (1) CN118119635A (https=)
AU (2) AU2022350407B2 (https=)
CA (1) CA3233075A1 (https=)
CL (1) CL2024000834A1 (https=)
CO (1) CO2024004910A2 (https=)
IL (1) IL311643A (https=)
MX (1) MX2024003535A (https=)
PE (1) PE20241994A1 (https=)
TW (1) TWI858393B (https=)
WO (1) WO2023045977A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3854805A4 (en) 2018-09-21 2022-08-24 Innovent Biologics (Suzhou) Co., Ltd. NOVEL INTERLEUKIN 2 AND ITS USE
JP2023518434A (ja) * 2020-03-19 2023-05-01 イノベント バイオロジクス（スーチョウ）カンパニー，リミティド インターロイキン２変異体およびその使用
WO2025007037A1 (en) * 2023-06-28 2025-01-02 Dragonfly Therapeutics, Inc. Variant il-2 proteins
WO2025031434A1 (zh) * 2023-08-08 2025-02-13 北京志道生物科技有限公司 经修饰的细胞因子与cd40激动剂的联用组合物及其抗肿瘤用途
WO2025140535A1 (zh) * 2023-12-28 2025-07-03 福佑泰生物制药（新加坡）公司 Pd-1/il-2r双特异性抗体融合蛋白及其用途和使用方法
CN118373896B (zh) * 2024-04-19 2025-07-29 上海科棋药业科技有限公司 抗pd-1抗体与il-2突变体的双功能融合蛋白
WO2025252212A1 (zh) * 2024-06-07 2025-12-11 福佑泰生物制药公司 抗pd-1抗体与细胞因子il-12突变蛋白的免疫缀合物以及其应用
WO2026012466A1 (en) * 2024-07-12 2026-01-15 Vibrant Pharma Limited Interleukin-2 muteins and uses thereof
CN118546233B (zh) * 2024-07-30 2024-10-18 成都微芯新域生物技术有限公司 白介素-21突变体及其应用
CN121293311A (zh) * 2025-08-01 2026-01-09 合肥天港免疫药物有限公司 Il-2变体及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201900220A (zh) * 2017-04-03 2019-01-01 瑞士商赫孚孟拉羅股份公司 免疫結合物
CN110003339A (zh) * 2015-08-10 2019-07-12 信达生物制药(苏州)有限公司 Pd-1抗体
TW202014432A (zh) * 2018-09-21 2020-04-16 大陸商信達生物製藥（蘇州）有限公司 新型白介素２及其用途
CN111655718A (zh) * 2017-12-19 2020-09-11 Xencor股份有限公司 经过工程化的il-2 fc融合蛋白

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
NZ234674A (en) * 1989-08-02 1992-02-25 Seragen Inc Mutant interleukin-2,dna encoding it, host cells, cytotoxic and toxin-mutant il-2 conjugates
DZ2788A1 (fr) 1998-05-15 2003-12-01 Bayer Ag Agonistes et antagonistes selectifs à IL-2.
US6955807B1 (en) * 1998-05-15 2005-10-18 Bayer Pharmaceuticals Corporation IL-2 selective agonists and antagonists
JP7148539B2 (ja) * 2017-04-03 2022-10-05 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 免疫抱合体
US12280118B2 (en) * 2017-12-27 2025-04-22 Kyowa Kirin Co., Ltd. IL-2 variant
WO2020252418A2 (en) * 2019-06-14 2020-12-17 Cugene, Inc. Novel interleukin-2 variants for the treatment of cancer
WO2020252421A2 (en) * 2019-06-14 2020-12-17 Cugene, Inc. Novel interleukin-2 variants and bifunctional fusion molecules thereof
JP2023518434A (ja) * 2020-03-19 2023-05-01 イノベント バイオロジクス（スーチョウ）カンパニー，リミティド インターロイキン２変異体およびその使用
AU2021237518B2 (en) * 2020-03-19 2024-08-15 Fortvita Biologics (Singapore) Pte.Ltd. Interleukin-2 mutant and use thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110003339A (zh) * 2015-08-10 2019-07-12 信达生物制药(苏州)有限公司 Pd-1抗体
TW201900220A (zh) * 2017-04-03 2019-01-01 瑞士商赫孚孟拉羅股份公司 免疫結合物
CN111655718A (zh) * 2017-12-19 2020-09-11 Xencor股份有限公司 经过工程化的il-2 fc融合蛋白
TW202014432A (zh) * 2018-09-21 2020-04-16 大陸商信達生物製藥（蘇州）有限公司 新型白介素２及其用途

Also Published As

Publication number Publication date
KR20240082364A (ko) 2024-06-10
PE20241994A1 (es) 2024-09-27
AU2022350407A1 (en) 2024-05-02
EP4406965A1 (en) 2024-07-31
WO2023045977A1 (zh) 2023-03-30
AU2022350407B2 (en) 2025-09-04
EP4406965A4 (en) 2025-12-17
JP2024534545A (ja) 2024-09-20
CN118119635A (zh) 2024-05-31
IL311643A (en) 2024-05-01
CA3233075A1 (en) 2023-03-30
AU2025275202A1 (en) 2026-02-19
CL2024000834A1 (es) 2024-09-06
US20240391973A1 (en) 2024-11-28
CO2024004910A2 (es) 2024-07-08
TW202320862A (zh) 2023-06-01
MX2024003535A (es) 2024-05-07
US20260053898A1 (en) 2026-02-26

Similar Documents

Publication Publication Date Title
TWI858393B (zh) 介白素２突變體以及其融合蛋白
TWI754800B (zh) 新型抗ox40/pd-l1雙特異性抗體分子、新型抗vegf/gitr雙特異性抗體分子及其用途
TWI826880B (zh) 白細胞介素２１突變體以及其用途
TWI772586B (zh) 三鏈抗體、其製備方法及其用途
WO2022042690A1 (zh) Ccr8抗体及其应用
WO2019184909A1 (zh) 新型抗体分子、其制备方法及其用途
KR20220137723A (ko) 항-cd3 및 항-cd123 이중 특이성 항체 및 이의 용도
JP2023550419A (ja) 二機能性分子
KR20230070238A (ko) 4-1bb를 표적으로 하는 단일 도메인 항체, 이의 융합 단백질, 이의 약제학적 조성물 및 용도
US20250144141A1 (en) Mage-a4 peptide dual t cell engagers
CN117062840A (zh) 靶向bcma的多特异性抗体
WO2023236991A1 (zh) 靶向her2，pd-l1和vegf的三特异性抗体
CN119894934A (zh) 结合lilrb4和cd3的抗体及其用途
US12545732B2 (en) PD-1 antigen-binding protein and use thereof
WO2025252212A1 (zh) 抗pd-1抗体与细胞因子il-12突变蛋白的免疫缀合物以及其应用
WO2025093033A1 (zh) 抗pd-1/cd40双特异抗体及其用途